A new FDA-approved drug to treat early-onset Alzheimer's disease is now being offered at UW Medicine's Harborview Medical Center for qualifying patients. Harborview is one of the first West Coast hospitals to administer the medication, described by doctors as a "breakthrough." It is giving hope to delay the effects of a devastating disease that to this day, has no cure. The medication, known as lecanemab, or by its brand name Leqembi, is designed for early-onset Alzheimer's patients who have mild cognitive decline.